A position statement on the management of patients with pityriasis rosea

  title={A position statement on the management of patients with pityriasis rosea},
  author={Antonio Chuh and Vijay P. Zawar and Gabriel F. Sciallis and Werner Kempf},
  journal={Journal of the European Academy of Dermatology and Venereology},
  • A. Chuh, V. Zawar, W. Kempf
  • Published 1 October 2016
  • Medicine
  • Journal of the European Academy of Dermatology and Venereology
Many clinical trials have been conducted on the treatment of pityriasis rosea (PR). Our aim was to establish a position statement for the management of adults with PR based on the best available evidence. We searched PubMed for all reports on randomized controlled trials for the treatment of PR published in the past 30 years. We retrieved 14 articles reporting randomized controlled trials, and found five which met our quality requirements for in‐depth analyses. Erythromycin was found in a well… 

The efficacy of oral acyclovir during early course of pityriasis rosea: a systematic review and meta-analysis

Oral acyClovir may be a relatively safe and effective treatment in the early course of PR, and patients with PR may achieve faster symptoms control with acyclovir.

Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis

Symptomatic treatment is a reasonable option for pityriasis rosea, and the addition of acyclovir is justified for the control of symptoms and pruritus.

Three Cases of Pityriasis Rosea in Child treated with Eunkyo-san

It is thought that Eunkyo-san has antiviral effect through the activation of immunological mechanism, and thus EunkyO-san appears to have a therapeutic effect on pityriasis rosea.

Pityriasis Rosea: Diagnosis and Treatment.

The differential diagnosis includes secondary syphilis, seborrheic dermatitis, nummular eczema, pityriasis lichenoides chronica, tinea corporis, viral exanthems, lichen planus, and pityriases rosea-like eruption associated with certain medications.

Clinical variants of pityriasis rosea

Atypical presentations of the disease are reviewed, including diverse forms of location and morphology of the lesions, the course of the eruption, and its differential diagnoses.

Infectious exanthemas in childhood

  • R. Fölster-Holst
  • Medicine
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • 2020
Diagnosing serious diseases with life‐threatening complications at an early stage is important for the timely initiation of adequate therapy and requires knowledge of the specific patterns of the exanthema, obtained from the medical history and the clinic, including the patient's general condition and physical examination.

Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea

Oral corticosteroids, even if used in low-dose and for a short tapering course should not be the first line of therapy for PR, because the only justified indication may be extensive and highly symptomatic lesions of PR.

Concurrent pityriasis rosea and Bell's palsy

A case of the 2 concurrent diagnoses that supports a common contributing factor and suggests further awareness and research into the role HHV 6–7 may play in the aetiology of both conditions is reported.

Dermatologic Problems Commonly Seen by the Allergist/Immunologist.



Efficacy of clarithromycin in pityriasis rosea.

Clarithromycin is not effective in treatment of pityriasis rosea and should not be considered as a treatment option, according to the authors.

Oral erythromycin is ineffective in the treatment of pityriasis rosea.

A placebo-controlled study on 184 patients with pityriasis rosea attending the outpatient dermatology department at Hazrat-e-Rasul Hospital in Tehran, Iran found no significant difference between the 2 treatment groups at weeks 4, 6, and 8 after beginning of treatment.

Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability

Acyclovir offered rapid resolution of clinical severity of PR from second week onwards without significantly increased adverse events as compared to supportive therapy alone.


It seemed that a high-dose of oral acyclovir was a safe and effective therapy for PR, although this remained to be confirmed in larger studies.

The efficacy of azithromycin in pityriasis rosea: a randomized, double-blind, placebo-controlled trial.

Azithromycin is not effective in pityriasis rosea and the use of macrolides for this disease should not be encouraged in clinical practice.

Use of high-dose acyclovir in pityriasis rosea.

The efficacy of macrolides and acyclovir in pityriasis rosea.

A fast response was obtained in 87 consecutive patients treated with high‐dose oral acyclovir, 800 mg given 5 times daily for 7 days, and the response was surprising since it was obtained after only 1 week, considering that, in most studies on the systemic treatment for pityriasis rosea, the effect was evaluated after 2 weeks.

Interventions for pityriasis rosea.

There is inadequate evidence for efficacy for most treatments for pityriasis rosea, but oral erythromycin may be effective in treating the rash and decreasing the itch and both dexchlorpheniramine and betamethasone alone seem to be better at clearing rash.

Comparative study of effectiveness of oral acyclovir with oral erythromycin in the treatment of Pityriasis rosea.

Although it is a self-limiting disease which resolves within three weeks to three months, this study reveals that both oral Acyclovir and oral Erythromycin are helpful in decreasing the severity and duration of Pityriasis rosea.